Literature DB >> 11384785

Adaptive designs, informed consent, and the ethics of research.

D Pullman1, X Wang.   

Abstract

The ethical tension in research design is often characterized as that between individual and collective ethics. While adaptive clinical trials (ACTs) are generally considered to be more sensitive to individual ethics, the concomitant loss of statistical power associated with them is often used to justify randomized clinical trials (RCTs). This paper challenges this characterization of the central ethical problem in research design. It argues that the key consideration in clinical research hinges on the process of informed consent. When the research context is such that the subject is able to provide informed consent, RCTs can be justified and may be required. However, in desperate medical situations the process of informed consent is often undermined. It is argued that in such situations ACTs are ethically required. We introduce "the principle of interchangeability" and argue that it must be satisfied if research in desperate medical situations is to be justified.

Keywords:  Biomedical and Behavioral Research

Mesh:

Year:  2001        PMID: 11384785     DOI: 10.1016/s0197-2456(01)00122-2

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  7 in total

1.  Response-adaptive decision-theoretic trial design: operating characteristics and ethics.

Authors:  Ari M Lipsky; Roger J Lewis
Journal:  Stat Med       Date:  2013-04-04       Impact factor: 2.373

2.  Adaptive trial design: could we use this approach to improve clinical trials in the field of global health?

Authors:  Trudie Lang
Journal:  Am J Trop Med Hyg       Date:  2011-12       Impact factor: 2.345

3.  Clinical trialist perspectives on the ethics of adaptive clinical trials: a mixed-methods analysis.

Authors:  Laurie J Legocki; William J Meurer; Shirley Frederiksen; Roger J Lewis; Valerie L Durkalski; Donald A Berry; William G Barsan; Michael D Fetters
Journal:  BMC Med Ethics       Date:  2015-05-03       Impact factor: 2.652

Review 4.  A Framework for Methodological Choice and Evidence Assessment for Studies Using External Comparators from Real-World Data.

Authors:  Christen M Gray; Fiona Grimson; Deborah Layton; Stuart Pocock; Joseph Kim
Journal:  Drug Saf       Date:  2020-07       Impact factor: 5.606

5.  Talking to the people that really matter about their participation in pandemic clinical research: A qualitative study in four European countries.

Authors:  Nina H Gobat; Micaela Gal; Christopher C Butler; Steve A R Webb; Nicholas A Francis; Helen Stanton; Sibyl Anthierens; Hilde Bastiaens; Maciek Godycki-Ćwirko; Anna Kowalczyk; Mariona Pons-Vigués; Enriqueta Pujol-Ribera; Anna Berenguera; Angela Watkins; Prasanth Sukumar; Ronald G Moore; Kerenza Hood; Alistair Nichol
Journal:  Health Expect       Date:  2017-09-27       Impact factor: 3.377

6.  The Ebola clinical trials: a precedent for research ethics in disasters.

Authors:  Philippe Calain
Journal:  J Med Ethics       Date:  2016-08-29       Impact factor: 2.903

7.  Stakeholder views regarding ethical issues in the design and conduct of pragmatic trials: study protocol.

Authors:  Stuart G Nicholls; Kelly Carroll; Jamie Brehaut; Charles Weijer; Spencer Phillips Hey; Cory E Goldstein; Merrick Zwarenstein; Ian D Graham; Joanne E McKenzie; Lauralyn McIntyre; Vipul Jairath; Marion K Campbell; Jeremy M Grimshaw; Dean A Fergusson; Monica Taljaard
Journal:  BMC Med Ethics       Date:  2018-11-20       Impact factor: 2.652

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.